“…The FSFI, originally developed for use in clinical trials of pharmacological treatment for male sexual dysfunction (Goldstein, et al, 2005), permits comparisons through cutoff scores established to distinguish sexual dysfunction in non-cancer populations (Rosen, et al, 2000). Our review also found examples of the FSFI successfully measuring change in sexual function over time (e.g., Carter, Sonoda, Chi, Raviv, & Abu-Rustum, 2008), effectiveness of interventions (e.g., Schover, et al, 2013), and differential impact of cancer treatment approaches (e.g., McGlone, Khan, Flashman, Khan, & Parvaiz, 2012). …”